<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9820334</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">36613952</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">9820334</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3390/ijms24010510</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">ijms-24-00510</article-id></all-ids><extracted-table><table-id>ijms-24-00510-t001</table-id><table-label>Table 1</table-label><table-caption>Gene expression network correlation analysis data corresponding to Figure 5 (baseline differences in resting-state and nociceptive functional connectivity.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="ijms-24-00510-t001"><object-id pub-id-type="pii">ijms-24-00510-t001_Table 1</object-id><label>Table 1</label><caption><p>Gene expression network correlation analysis data corresponding to <xref rid="ijms-24-00510-f005" ref-type="fig">Figure 5</xref> (baseline differences in resting-state and nociceptive functional connectivity.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Resting State</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT vs. α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT vs. Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT vs. SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Bs, cxAss, cxS</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, cxS, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, cxS<break/>↓: Bs</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Bs, cxAss, Hy, Am, Bg</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss<break/>↓: Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, Am, Bg<break/>↓: Bs, Hy, Am</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↓: Hy, Bg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nociception</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT vs. α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT vs. Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT vs. SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">↓: Th, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Th, Hc</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">↓: Bs, Hy, Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Bs, Hy, Am</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Gene expression network correlation analysis highlighted which neurotransmitters may be involved in the depicted differences. ↓: functional connectivity is reduced in the indicated mouse model compared to WT, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced in the indicated mouse model compared to WT, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), Hy (hypothalamus), Th (thalamus).</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>ijms-24-00510-t001_Table 1Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Gene expression network correlation analysis data corresponding to ??? (baseline differences in resting-state and nociceptive functional connectivity.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Resting State</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WT vs. α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WT vs. Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WT vs. SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle">↓: Bs, cxAss, cxS</td><td align="center" valign="middle">↑: cxAss, cxS, Hc</td><td align="center" valign="middle">↑: cxAss, cxS↓: Bs</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle">↓: Bs, cxAss, Hy, Am, Bg</td><td align="center" valign="middle">↑: cxAss↓: Am</td><td align="center" valign="middle">↑: cxAss, Am, Bg↓: Bs, Hy, Am</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin">↓: Hy, Bg</td><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin">Nociception</td><td align="center" valign="middle" style="border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin">WT vs. α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">WT vs. Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">WT vs. SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle"/><td align="center" valign="middle">↓: Th, Hc</td><td align="center" valign="middle">↓: Th, Hc</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle"/><td align="center" valign="middle">↓: Bs, Hy, Am</td><td align="center" valign="middle">↓: Bs, Hy, Am</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/></tr></tbody></table></div>Gene expression network correlation analysis highlighted which neurotransmitters may be involved in the depicted differences. ↓: functional connectivity is reduced in the indicated mouse model compared to WT, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced in the indicated mouse model compared to WT, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), Hy (hypothalamus), Th (thalamus).</transformed-table></extracted-table><extracted-table><table-id>ijms-24-00510-t002</table-id><table-label>Table 2</table-label><table-caption>Gene expression network correlation analysis data corresponding to Figure 6 (nociception). Data provide an overview of which neurotransmitters (of those modulated in our mouse models) are mainly expressed in the affected brain regions.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="ijms-24-00510-t002"><object-id pub-id-type="pii">ijms-24-00510-t002_Table 2</object-id><label>Table 2</label><caption><p>Gene expression network correlation analysis data corresponding to <xref rid="ijms-24-00510-f006" ref-type="fig">Figure 6</xref> (nociception). Data provide an overview of which neurotransmitters (of those modulated in our mouse models) are mainly expressed in the affected brain regions.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Baseline vs. D5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: cxS, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Hc<break/>↓: Th, cxAss, cxS</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxS (right)<break/>↓: cxS (left)</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Th, cxAss, cxS, Hc</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, cxAss, Am, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Baseline vs. D21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxS, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxS<break/>↓: Bs, Th, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxS, Hc</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, Hc, PAG</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Bs, PAG</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Am, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Hc</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>↓: functional connectivity is reduced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), PAG (periaqueductal grey), Th (thalamus).</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>ijms-24-00510-t002_Table 2Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Gene expression network correlation analysis data corresponding to ??? (nociception). Data provide an overview of which neurotransmitters (of those modulated in our mouse models) are mainly expressed in the affected brain regions.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Baseline vs. D5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WT</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle">↓: cxS, Hc</td><td align="center" valign="middle">↑: Hc↓: Th, cxAss, cxS</td><td align="center" valign="middle">↑: cxS (right)↓: cxS (left)</td><td align="center" valign="middle">↑: Bs, Th, cxAss, cxS, Hc</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle">↑: Am</td><td align="center" valign="middle">↑: Am</td><td align="center" valign="middle">↑: Bs, Am</td><td align="center" valign="middle">↑: Bs, cxAss, Am, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin">Baseline vs. D21</td><td align="center" valign="middle" style="border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin">WT</td><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle">↑: cxS, Hc</td><td align="center" valign="middle">↑: cxS↓: Bs, Th, Hc</td><td align="center" valign="middle">↑: Hc</td><td align="center" valign="middle">↑: cxS, Hc</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle">↑: cxAss, Hc, PAG</td><td align="center" valign="middle">↓: Bs, PAG</td><td align="center" valign="middle">↑: Bs, Am, Hc</td><td align="center" valign="middle">↑: Hc</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/></tr></tbody></table></div>↓: functional connectivity is reduced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), PAG (periaqueductal grey), Th (thalamus).</transformed-table></extracted-table><extracted-table><table-id>ijms-24-00510-t003</table-id><table-label>Table 3</table-label><table-caption>Gene expression network correlation analysis data corresponding to Figure 7 (resting state). Data provide an overview of which neurotransmitters (of those modulated by our mouse models) are mainly expressed in the affected brain regions.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="ijms-24-00510-t003"><object-id pub-id-type="pii">ijms-24-00510-t003_Table 3</object-id><label>Table 3</label><caption><p>Gene expression network correlation analysis data corresponding to <xref rid="ijms-24-00510-f007" ref-type="fig">Figure 7</xref> (resting state). Data provide an overview of which neurotransmitters (of those modulated by our mouse models) are mainly expressed in the affected brain regions.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Baseline vs. D5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WT</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, cxS</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Th, cxAss, cxS, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss (left) <break/>cxS (left)<break/>↓: Bs, Th, cxAss (right), cxS (right), Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Th, cxAss, cxS, Hc</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: Am, Hy</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, Am, Hy, Bg<break/>↓: Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↓: cxAss, Bs, Am, Hy</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, cxAss, Am, Hy, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↑: Cb</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Baseline vs. D21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYX</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Noradrenaline</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, cxS</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, Th, cxAss, cxS, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, cxS<break/>↓: Bs, Hc</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs<break/>↓: cxAss, cxS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Substance P</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, cxAss, Am, Bg<break/>↓: Am</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Bs, cxAss, Am, Hy, Bg</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: cxAss, Bg<break/>↓: Bs, Am, Hy</td><td align="center" valign="middle" rowspan="1" colspan="1">↑: Am<break/>↓: Bs, cxAss, Hy, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↑: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>↓: functional connectivity is reduced at days 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), Cb (cerebellum), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), Hy (hypothalamus), Th (thalamus).</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>ijms-24-00510-t003_Table 3Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Gene expression network correlation analysis data corresponding to ??? (resting state). Data provide an overview of which neurotransmitters (of those modulated by our mouse models) are mainly expressed in the affected brain regions.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Baseline vs. D5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WT</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">α-CGRP−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Tac1−/−</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle">↑: cxAss, cxS</td><td align="center" valign="middle">↑: Bs, Th, cxAss, cxS, Hc</td><td align="center" valign="middle">↑: cxAss (left) cxS (left)↓: Bs, Th, cxAss (right), cxS (right), Hc</td><td align="center" valign="middle">↑: Bs, Th, cxAss, cxS, Hc</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle">↓: Am, Hy</td><td align="center" valign="middle">↑: cxAss, Am, Hy, Bg↓: Am</td><td align="center" valign="middle">↓: cxAss, Bs, Am, Hy</td><td align="center" valign="middle">↑: Bs, cxAss, Am, Hy, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin"/><td align="center" valign="middle" style="border-bottom:solid thin">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin">↑: Cb</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin">Baseline vs. D21</td><td align="center" valign="middle" style="border-bottom:solid thin">Neurotransmitter</td><td align="center" valign="middle" style="border-bottom:solid thin">WT</td><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">Tac1−/−</td><td align="center" valign="middle" style="border-bottom:solid thin">SYX</td></tr><tr><td align="center" valign="middle">Noradrenaline</td><td align="center" valign="middle">↑: Bs, cxS</td><td align="center" valign="middle">↑: Bs, Th, cxAss, cxS, Hc</td><td align="center" valign="middle">↑: cxAss, cxS↓: Bs, Hc</td><td align="center" valign="middle">↑: Bs↓: cxAss, cxS</td></tr><tr><td align="center" valign="middle">Substance P</td><td align="center" valign="middle">↑: Bs, cxAss, Am, Bg↓: Am</td><td align="center" valign="middle">↑: Bs, cxAss, Am, Hy, Bg</td><td align="center" valign="middle">↑: cxAss, Bg↓: Bs, Am, Hy</td><td align="center" valign="middle">↑: Am↓: Bs, cxAss, Hy, Bg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin">α-CGRP</td><td align="center" valign="middle" style="border-bottom:solid thin">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin">↑: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin">↓: Cb</td><td align="center" valign="middle" style="border-bottom:solid thin"/></tr></tbody></table></div>↓: functional connectivity is reduced at days 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. ↑: functional connectivity is enhanced at day 5/21 compared to baseline, and the brain regions express the indicated neurotransmitter. Abbreviations: Am (amygdala), Bg (basalganglia), Bs (brainstem), Cb (cerebellum), cxS (somatosensory cortex), cxAss (association cortex), Hc (hippocampus), Hy (hypothalamus), Th (thalamus).</transformed-table></extracted-table><extracted-table><table-id>ijms-24-00510-t004</table-id><table-label>Table 4</table-label><table-caption>Overview of the animal cohorts and numbers.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="ijms-24-00510-t004"><object-id pub-id-type="pii">ijms-24-00510-t004_Table 4</object-id><label>Table 4</label><caption><p>Overview of the animal cohorts and numbers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"/><th align="right" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Treatment Duration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2" colspan="1">−2 Days<break/>Before Fracture</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2" colspan="1">5 Days<break/>Post Fracture</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2" colspan="1">21 Days<break/>Post Fracture</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mouse Models</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="center" valign="middle" colspan="2" rowspan="1">Wildtype (WT)</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">5<break/>(+3 of cohort 2 for biomechanical tests)</td></tr><tr><td align="center" valign="middle" colspan="2" rowspan="1">alpha-CGRP-<italic toggle="yes">knockout</italic> (α-CGRP−/−)</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" colspan="2" rowspan="1">Tachykinin-1-<italic toggle="yes">knockout</italic> (Tac1−/−)</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" colspan="2" rowspan="1">Sympathectomized WT (SYX)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (−1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (−1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (−1)</td></tr></tbody></table><table-wrap-foot><fn><p>Numbers in columns represent the numbers of animals, used for fMRI analysis at time points −2 days before fracture, and 5 and 21 days post fracture. After time point day 5, animals were divided into two study cohorts—cohort 1 and cohort 2. Animal numbers of cohort 1 are listed at day 21 and were used for fMRI analysis plus µCT and biomechanical tests, addressed in the present study. Cohort 2 underwent a different treatment and will not be addressed here with one exception: femora of 3 WT animals were used for biomechanical tests on day 21 for the present study as replacement for femora of 2 WT mice that collapsed during preparation for biomechanical tests (i.e., breakdown of diaphysis at fracture site; see Group assignment and dropout; mice were numbered as +3 in brackets at day 21). One SYX mouse died during the first fMRI analysis at day −2 and had to be excluded from the study (numbered as −1 in brackets). Mouse model names in brackets refer to abbreviations used in the figures.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>ijms-24-00510-t004_Table 4Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Overview of the animal cohorts and numbers.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin"/><th align="right" valign="middle" style="border-top:solid thin">Treatment Duration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2">−2 DaysBefore Fracture</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2">5 DaysPost Fracture</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="2">21 DaysPost Fracture</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin">Mouse Models</th><th align="center" valign="middle" style="border-bottom:solid thin"/></tr></thead><tbody><tr><td align="center" valign="middle" colspan="2">Wildtype (WT)</td><td align="center" valign="middle">13</td><td align="center" valign="middle">13</td><td align="center" valign="middle">5(+3 of cohort 2 for biomechanical tests)</td></tr><tr><td align="center" valign="middle" colspan="2">alpha-CGRP-knockout (α-CGRP−/−)</td><td align="center" valign="middle">9</td><td align="center" valign="middle">9</td><td align="center" valign="middle">5</td></tr><tr><td align="center" valign="middle" colspan="2">Tachykinin-1-knockout (Tac1−/−)</td><td align="center" valign="middle">9</td><td align="center" valign="middle">9</td><td align="center" valign="middle">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" colspan="2">Sympathectomized WT (SYX)</td><td align="center" valign="middle" style="border-bottom:solid thin">8 (−1)</td><td align="center" valign="middle" style="border-bottom:solid thin">8 (−1)</td><td align="center" valign="middle" style="border-bottom:solid thin">4 (−1)</td></tr></tbody></table></div>Numbers in columns represent the numbers of animals, used for fMRI analysis at time points −2 days before fracture, and 5 and 21 days post fracture. After time point day 5, animals were divided into two study cohorts—cohort 1 and cohort 2. Animal numbers of cohort 1 are listed at day 21 and were used for fMRI analysis plus µCT and biomechanical tests, addressed in the present study. Cohort 2 underwent a different treatment and will not be addressed here with one exception: femora of 3 WT animals were used for biomechanical tests on day 21 for the present study as replacement for femora of 2 WT mice that collapsed during preparation for biomechanical tests (i.e., breakdown of diaphysis at fracture site; see Group assignment and dropout; mice were numbered as +3 in brackets at day 21). One SYX mouse died during the first fMRI analysis at day −2 and had to be excluded from the study (numbered as −1 in brackets). Mouse model names in brackets refer to abbreviations used in the figures.</transformed-table></extracted-table></extracted-tables-set>